Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of B-cell lymphoma that has come back or not responded to treatment (like diffuse large B-cell lymphoma, mantle cell lymphoma, or others).
- Your tumor cells have a protein called CD19 (a test on your biopsy can confirm this).
- You have at least one tumor that is at least 1.5 cm on a scan.
- Your heart, liver, and kidneys are working well enough, and you are not pregnant or breastfeeding.
- You have not had active infections (like hepatitis B or C, HIV) or a history of other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
This trial tests a new type of CAR T-cell therapy that targets three proteins (CD19, CD20, and CD22) on lymphoma cells. It's for people with B-cell lymphomas that have come back or not responded to at least two prior treatments.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
This Phase 1/2 study tests cord blood–derived CAR NK cells that are designed to attack lymphoma cells marked with CD19 and/or CD70. It is for people whose B-cell non-Hodgkin lymphoma has come back or did not respond to prior treatment, including CAR-T when applicable.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This early-phase study tests “humanized” CD19 CAR-T therapy for people whose B-cell acute lymphoblastic leukemia (ALL) or B-cell lymphoma (NHL) has come back or didn’t respond. It’s designed to help the immune system recognize and attack cancer cells carrying the CD19 marker.
Hear when a new Primary Mediastinal B-cell Lymphoma (PMBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.